Target intelligence / Profile preview

Multiple intracellular mRNA targets via miRNA cargo

Molecular classification
Messenger RNA (mRNA), Non-coding RNA
01

Overview

Multiple intracellular mRNA targets via miRNA cargo refers to a therapeutic modality rather than a single molecular entity. This approach utilizes microRNAs (miRNAs)—small, non-coding RNA molecules—to simultaneously regulate a broad network of messenger RNA (mRNA) transcripts within a cell (Bartel, D. P., Cell, 2004). Unlike traditional small molecules that target a single protein, a single miRNA can bind to the 3' untranslated regions (UTRs) of hundreds of different mRNAs, allowing for the coordinated modulation of entire biological pathways (Rupaimoole, R., & Slack, F. J., Nature Reviews Drug Discovery, 2017). This strategy is particularly valuable in treating complex diseases like cancer, where multiple oncogenic drivers must be suppressed to prevent therapeutic resistance (Kalluri, R., & LeBleu, V. S., Science, 2020). The miRNA cargo is typically encapsulated in delivery vehicles such as lipid nanoparticles (LNPs) or exosomes to protect the RNA from degradation and facilitate cellular uptake. Once inside the cytoplasm, the miRNA integrates into the RNA-induced silencing complex (RISC) to mediate post-transcriptional gene silencing through mRNA cleavage or translational repression (Adams, B. D., et al., Molecular Therapy, 2017).

Other names
miRNA-mediated gene silencingmicroRNA-target networksmiRNA-mRNA interactomePost-transcriptional gene regulation network
02

Mechanism of action

miRNAs are delivered into the intracellular environment (often via exosomes or lipid nanoparticles) where they are loaded into the RNA-induced silencing complex (RISC). The miRNA then acts as a guide to bind complementary sequences, typically in the 3' untranslated regions (UTRs), of multiple target mRNAs, leading to their degradation or the inhibition of their translation.

03

Biological functions

Post-transcriptional gene regulationRNA interferenceGene silencingTranslation inhibitionCell differentiation
04

Disease associations

CancerCardiovascular diseaseNeurodegenerative diseaseMetabolic disordersInflammation
05

Safety considerations

Off-target gene silencingSevere innate immune activation (cytokine storm)Saturation of endogenous RNAi machineryDose-limiting liver and kidney toxicityDelivery vehicle-associated immunogenicity
06

Interacting drugs

Remlarsen (MRG-201)

4 more in the full profile.

07

Biomarkers

miRNA expression signaturesTarget mRNA expression levelsCirculating exosome concentrationRISC complex activity

Beyond the preview

Go deeper on Multiple intracellular mRNA targets via miRNA cargo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multiple intracellular mRNA targets via miRNA cargo.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call